List view / Grid view
7 July 2016 | By Victoria White, Digital Content Producer
The EGALITY study involved 531 patients and compared the efficacy and safety of biosimilar etanercept with the originator product, Enbrel...
1 July 2016 | By Victoria White, Digital Content Producer
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
29 June 2016 | By Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination...
Enstilar is the first fixed-combination, cutaneous foam spray for the once-daily topical treatment of all extents of plaque psoriasis...
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
26 April 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...
The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.
6 April 2016 | By Victoria White, Digital Content Producer
With this approval, Celltrion's Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US...
23 March 2016 | By Victoria White
Taltz (ixekizumab) is intended for adult patients who are candidates for systemic therapy, phototherapy or a combination of both...
21 March 2016 | By Victoria White
Enstilar is a topical spray foam treatment for psoriasis that is designed to provide patients with a convenient treatment option that can be easily applied...
8 March 2016 | By Victoria White
In UNCOVER-2, patients with plaque psoriasis who did not respond to etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
7 March 2016 | By Victoria White
These data show the enhanced local bioavailability of calcipotriol/betamethasone dipropionate in the foam spray vehicle results from supersaturation...
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
